# A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants

> **NCT04722484** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 39 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Vericiguat (BAY1021189)

## Key facts

- **NCT ID:** NCT04722484
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-12
- **Primary completion:** 2015-01-22
- **Final completion:** 2015-01-22
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2021-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04722484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04722484, "A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04722484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*